Testing a blood test to predict liver cancer coming back
Part of Cancer, Digestive system clinical trials.
This study checks whether a blood test (circulating tumor DNA) can help predict if hepatocellular carcinoma (HCC) will return after curative treatment like surgery or ablation. If it works, it may help doctors plan closer follow-up or earlier treatment if recurrence risk is higher.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have liver cancer (HCC) that fits specific imaging criteria in people with cirrhosis, or it was confirmed by biopsy when scans were unclear
- You already had curative treatment for the liver tumor, such as surgical removal or radiofrequency ablation
- Your treatment plan was officially confirmed by the digestive oncology team
- You understand the study and sign the permission form
- You can follow up at Charles Nicolle University Hospital in Rouen
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a blood test that tracks circulating tumor cells (CTCs) can help doctors detect early signs of liver cancer returning after surgery. It aims to give patients and their doctors a better way to monitor for recurrence.
This study uses a blood test (looking at sugars in the blood) to help predict whether liver cancer will come back after a liver transplant. It may help doctors monitor you more accurately and earlier if cancer returns.
This trial tests a new blood test to help detect liver cancer (HCC) or confirm it’s not present in people with cirrhosis who are being monitored. It may help improve how doctors screen for liver cancer and decide who needs further imaging or treatment.
This study looks at genetic markers in the blood of people with liver cancer who are having surgery, either right away or after some treatment first. It aims to find out why some patients do better, which could help personalize care.
This study looks for a new blood marker that may predict how well liver cancer will respond to radiation and what outcomes to expect. It’s for people with hepatitis B–related liver cancer who can safely receive radiation to the liver tumor.
This study looks at how well doctors can detect small, early liver cancer and then follow how it changes over time. It may help your care team choose the best next steps based on earlier, clearer detection.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.